Chapter 5. Reality check: What science has to tell us about psychiatric drugs and their long-term effects

Journal of College Student Psychotherapy

Volumn 21, Issue 3-4, 2007, Pages 97-123

  Whitaker, Robert B ^a  

^a NONE

Author keywords

Bio chemical perturbation; Chemical imbalance theory; Metal disability rates; Psychiatric drugs; Psychiatric treatment outcomes

Indexed keywords

EID: 34548774058     PISSN: 87568225     EISSN: 15404730     Source Type: Journal    
DOI: 10.1300/J035v21n03_05     Document Type: Article

References (67)

1. Arana G. (1999). An overview of side effects caused by typical antipsychotics (quotation is from discussion section.) Psychiatric Annals, 29, 657-660.
2. Babyak M., Blumenthal J., Herman S., Khatri P. et al. (2000). Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosomatic Medicine, 62, 633-638.
3. Ballenger J., Burrows G., DuPont R., Lesser I., Noyes R., Pecknold J. et al. (1988). Alprazolam, in panic disorder and agoraphobia: Results from a multi-center trial. Archives of General Psychiatry, 45, 413-21.
4. Blackburn I., Eunson K., & Bishop S. (1986). A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. Journal of Affective Disorders, 10, 67-75.
5. Bockoven J., & Solomon H. (1975). Comparison of two five-year follow-up studies: 1947-1952 and 1967-1972. American Journal of Psychiatry, 132, 796-801.
6. Bola J.Mosher L. (2003). Treatment of acute psychosis without neuroleptics: two-year outcomes from, the Soteria Project. Journal of Nervous Mental Disease, 191, 219-29.
7. Bourguignon R. (1997). Dangers of Fluoxetine, The Lancet, 394, 214.
8. Bowers M. (1974). Central dopamine turnover in schizophrenic syndromes. Archives of General Psychiatry, 31, 50-54.
9. Breggin P. (2003-2004). Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A. review and analysis. International Journal of Risk & Safety in Medicine, 16, 31-49.
10. Burt D., Creese I., & Snyder S. (1977). Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain, Science, 196, 326-328.
11. Carlezon W., Mague S., & Andersen S. (2003). Enduring biological effects of early exposure to methylphenidate in rats. Biological Psychiatry, 54, 1330-7.
12. Carpenter W., McGlashan T., & Strauss J. (1977). The treatment of acute schizophrenia without drugs: An investigation of some current assumptions. American Journal of Psychiatry, 134, 14-20.
13. Chakos M., Lieberman J., Bilder R, Borenstein M., Lerner G., Bogerts B. et al. (1994). Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry, 151, 1430-6.
14. Chouinard G., Jones B., & Annable L. (1978). Neuroleptic-induced supersensitivity psychosis. American Journal of Psychiatry, 135, 1409-10.
15. Chouinard G., & Jones B. (1980). Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. American Journal of Psychiatry, 137, 16-20.
16. Ciompi L., Dauwalder H., Maier C., Aebi E., Trutsch K., Küpper Z. et al. (1992). The Pilot Project Soteria Berne. British Journal of Psychiatry, 161 (Suppl 18), 145-53.
17. Cullberg J. (1999). Integrating psychosocial therapy and low-dose medical treatment in a total material of first episode psychotic patients compared to treatment as usual: a three-year followup. Medical Archives, 53, 167-70.
18. Cullberg J., Levander S., Holmqvist R., MattsonM., & Wieselgren I. (2002). One-year outcome in first episode psychosis patients in the Swedish Parachute Project. Acta Psychiatr Scand, 106, 276-85.
19. De Hert M., van Eyck D., & De Nayer A. (2006). Metabolic abnormalities associated with second generation, antipsychotics: Fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol, 21(Suppl 2), S11-5.
20. Elkin I. National Institute of Mental Health Treatment of Depression Collaborative Research Program. (1990). General effectiveness of treatments. Archives of General Psychiatry, 47, 682-688.
21. Fava G. (1994). Do antidepressant and antianxiety drugs increase chronicity in affective disorders? Psychotherapy and Psychosomatics, 61,125-31.
22. Fava G. (2003). Can long-term treatment with antidepressant drugs worsen the course of depression? Journal of Clinical Psychiatry, 64, 123-133.
23. Gardos G., Cole J. (1977). Maintenance antipsychotic therapy: Is the cure worse than the disease? American Journal of Psychiatry, 133, 32-6.
24. Geddes J., Freemantle N., Harrison P., & Bebbington P. (2000). Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal, 321, 1371-6.
25. Greenberg R., & Fisher S. (1997). Mood-mending medicines: probing drug, psychotherapy and placebo solutions. From Placebo to Panacea, John Wiley & Sons, 147.
26. Gur R., Cowell P., Turetsky B., Gallacher F., Cannon T., Bilker W. et al. (1998). A. follow-up magnetic resonance imaging study of schizophrenia. Archives of General Psychiatry, 55, 142-52.
27. Gur R., Maany V., Mozley D., Swanson C., & Bilker W. (1998). Subcortical MRI volumes in neuroleptic-na'ive and treated patients with schizophrenia. American Journal of Psychiatry, 55, 1711-7.
28. Haracz J. (1982). The dopamine hypothesis: An overview of studies with schizophrenic patients. Schizophrenia Bulletin, 8,438-458.
29. Healy D. (2005). Ads for SSRI antidepressants are misleading. PloS Medicine news release, November 2005.
30. Howland R. (1996). Induction of mania with serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology, 16, 425-427.
31. Hyman S., & Nestler E. (1996). Initiation and adaptation: A paradigm for understanding psychotropic drug action. American Journal of Psychiatry, 153, 151-161.
32. Hypericum, depression trial study group (2002). Effect of Hypericum, perforatum (St. John's wort) in major depressive disorder. JAMA, 287, 1807-14.
33. Jablensky A., Sartorius N., Ernberg G., Ansker M., Korten A., Cooper J. et al. (1992). Schizophrenia: Manifestations, incidence and course in different cultures, A World Health Organization ten-country study. Psychol Med 20(Monograph Suppl): 1095.
34. Jacobs, B. (1991). Serotonin and behavior: emphasis on motor control. Journal of Clinical Psychiatry, 52 (12 Suppl), .151-162.
35. Kane J., & Freeman H. (1994). Towards more effective antipsychotic treatment. British Journal of Psychiatry, 165, 22-31.
36. Kemker, S. (1995). Essay in Pseudoscience in Biological Psychiatry, ed. Colin Ross and Alvin Pam. (John Wiley and Sons, 1995), 246.
37. Khan A., Warner H., & Brown W. (2000). Symptom reduction, and suicide risk in patients treated with placebo in antidepressant clinical trials. Archives of General Psychiatry, 57, 311-317.
38. Kirsch I., & Moore T. (2002). The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention and Treatment, 5, article 23.
39. 3H-Siperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. Journal of Neural Transmission, 75, 1-10.
40. Lacasse, J., & Leo, J. (2005). Serotonin and depression: A disconnect between the advertisements and the scientific literature. PloS Medicine, 2, 1211-1216.
41. 3H-apomorphine in schizophrenic brains. Nature, 374, 897-900.
42. Leff J., Sartorius N., Körten A., & Ernberg G. (1992). The international pilot study of Schizophrenia: Five-year follow-up findings. Psychol Med, 22, 131-45.
43. Lehtinen V., Aaltonen J., Koffert T., Rakkolainen V., & Syvalahti E. (2000). Two-year outcome in first-episode psychos treated according to an integrated model. Is immediate neuroleptisation always needed? European Psychiatry, 15, 312-20.
44. Lehtinen K. (2001). Finnish needs-adapted project: 5-year outcomes. Madrid Spain: World Psychiatric Association International Congress, 2001.
45. Leo J. (2003). Broken brains or flawed, studies? A. critical review of ADHD neuroimaging research. The Journal of Mind and Behavior, 24, 29-56.
46. Liebzeit K., .Markowitz J., Caley C. (2001). New onset diabetes and atypical antipsychotics. Eur Neuropsycholpharmacol, 11, 25-32.
47. Mackay A., Iverson L, Rossor M., Spokes E., Bird E., Arregui A., Creese I., & Snyder S. (1982). Increased brain dopamine and dopamine receptors in schizophrenia. Archives of General Psychiatry, 39, 991-997.
48. Madsen A., Keiding A., Karle A., Esbjerg S., & Hemmingsen R. (1998). Neuroleptics in progressive structural brain abnormalities in psychiatric illness. The Lancet, 352, 784-5.
49. Marks I., Swinson R., Basoglu M., Kuch K. et al. (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia. British Journal of Psychiatry, 162, 790-794.
50. Mathews S., Roper M., Mosher L., & Menn A. (1979). A non-neuroleptic treatment for schizophrenia: Analysis of the two-year postdischarge risk of relapse. Schizophrenia Bulletin, 5, 322-32.
51. McDonagh MS, Peterson K. (2006). Drug class review on pharmacological treatments for ADHD: Final report, 2006. www.oshu.edu/drageffectiveness/.
52. Medical Research Council. (1965). Clinical trial of the treatment of depressive illness. British Medical Journal, 881-6.
53. Moore T. (1997). Hard to Swallow, Washingtonian, December 1997.
54. National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. (1964). "Phenothiazine treatment in acute schizophrenia." Archives of General Psychiatry, 10, 246-61.
55. Newcomer J. (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19 (Supple 1), 1-93.
56. Pecknold J., Swinson R., Kuch K., & Lewis C. (1988). Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial: Discontinuation effects. Archives of General Psychiatry, 45, 429-36.
57. Post R., Fink E., Carpenter W., & Goodwin F. (1975). Cerebrospinal fluid amine metabolites in acute schizophrenia. Archives of General Psychiatry, 32, 1063-1068.
58. Preda A., MacLean C., Mazure C., & Bowers M. (2001). Antidepressant-associated mania and psychosis resulting in psychiatric admission, Journal of Clinical Psychiatry, 62, 30-33.
59. Prien, R., Levine J., & Switalksi R. (1971). Discontinuation of chemotherapy for chronic schizophrenics. Hospital Community Psychiatry, 22, 20-3.
60. Rappaport M., Hopkins H., Hall K., Belleza T., & Silverman J. (1978). Are there schizophrenics for whom drugs may be unnecessary or contraindicated. Int Pharmacopsychiatry, 13, 100-11.
61. Schooler N., Goldberg S., Boothe H., & Cole J. (1967). One year after discharge: Community adjustment of schizophrenic patients. American Journal of Psychiatry, 123, 986-95.
62. Seikkula J., Alakare B., & Aaltonen J. (2000). A two-year followup on open dialogue treatment in first episode psychosis: Need for hospitalization and neuroleptic medication decreases. Social and Clinical Psychiatry, 10, 20-29.
63. Smith A., Traganza E., & Harrison G. (1969), Studies on the effectiveness of antidepressant drugs. Psychopharmacology Bulletin, 5, 1-20.
64. Thomson R. (1982). Side-effects and placebo amplification. British Journal of Psychiatry, 140, 64-68.
65. Torrey, E. (2001). The Invisible Plague: The Rise of Mental Illness from 1750 to the Present, Rutgers University Press, 315.
66. Volkow N., Ding Y., Fowler J., Wang G. et al. (1995). Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Archives of General Psychiatry, 52, 456-463.
67. 10 dopamine neurons. Science, 221, 1054-1056.